Special Issue Article
Transcatheter Closure of Patent Ductus Arteriosus
Tharakanatha R. Yarrabolu and P. Syamasundar Rao*
Department of Pediatrics, Division of Pediatrics Cardiology, University of Texas Health Science Center at Houston, Houston, Texas, USA
- *Corresponding Author:
- P. Syamasundar Rao, MD
Professor of Pediatrics & Medicine
Emeritus Chief of Pediatric Cardiology
UT-Houston Medical School, 6410 Fannin Street
UTPB Suite # 425, Houston, TX 77030
E-mail: [email protected]
Received Date: June 15, 2012; Accepted Date: July 28, 2012; Published Date: July 02, 2012
Citation: Yarrabolu TR, Syamasundar Rao P (2012) Transcatheter Closure of Patent Ductus Arteriosus. Pediat Therapeut S5:005. doi: 10.4172/2161-0665.S5-005
Copyright: © 2012 Yarrabolu TR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Patent ductus arteriosus (PDA) constitutes 6 to 11% of all congenital heart defects. While surgical ligation and video-assisted, thoracoscopic interruption of PDA are still available, transcatheter occlusion of PDAs has recently assumed a major role in closure of PDA. A large number of devices have been designed and tested both in animal models and human subjects, but only few devices (free and detachable Gianturco coils, GGVOD and Amplatzer duct occluder) are approved by the FDA for general clinical use. A few other devices are in clinical trials and are available only at institutions participating in clinical trials within or outside the US. At the present time, Gianturco coils for closure of very small and small PDAs and Amplatzer duct occluder for occlusion of small, moderate and large PDAs appear to be feasible, safe and effective in the majority of patients.